Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Robert A. Di Cicco"'
Publikováno v:
The Journal of Clinical Pharmacology. 40:1516-1521
Rosiglitazone is a potent insulin-sensitizing oral hypoglycemic agent of the thiazolidinedione class that works through activation of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptor and improves glycemic control in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::750890560463da0aeb05115402a1e6ea
https://doi.org/10.1177/009127000004001225
https://doi.org/10.1177/009127000004001225
Autor:
Martin I. Freed, Robert A. Di Cicco, Diane K. Jorkasky, Alison M Carr, Ann Allen, Susan Fowles
Publikováno v:
The Journal of Clinical Pharmacology. 40:1280-1285
Rosiglitazone is a potent oral antidiabetic agent of the thiazolidinedione class that works through activation of the peroxisome proliferator-activated nuclear receptor. It improves insulin sensitivity in peripheral tissues and effectively lowers blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cf1aaaeb1c5bcdef96aac5a32d16d68
https://doi.org/10.1177/009127000004001113
https://doi.org/10.1177/009127000004001113
Autor:
Lana Peng, Marcella Tucci, Robert A. Di Cicco, Diane K. Jorkasky, Sunita B. Sheth, Lisa J. Benincosa, Marcie J. Hursting, Jonathan Q. Tran
Publikováno v:
The Journal of Clinical Pharmacology. 39:513-519
Argatroban, a direct thrombin inhibitor, is metabolized in vitro by CYP3A4/5 and therefore may be susceptible to clinically relevant CYP3A drug interactions. The effect of erythromycin, a potent CYP3A4/5 inhibitor, on the pharmacokinetics and pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0ab424da65b713aa8c76954fb8470a4
https://doi.org/10.1177/009127009903900512
https://doi.org/10.1177/009127009903900512
Autor:
Ann K. Miller, Névine Zariffa, Steven C. Boike, Jerome J. Schentag, David E. Nix, Duane A. Boyle, Robert A. Di Cicco, Diane K. Jorkasky
Publikováno v:
Journal of clinical pharmacology. 39(8)
The potential for nonprescription cimetidine (200 mg twice daily) to affect the pharmacokinetics of sustained-release (SR) theophylline was assessed in 26 male subjects, 13 smokers and 13 nonsmokers. This was a concentration-controlled drug interacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fbbd8956f3302e70c28e48cf1b04a50
https://pubmed.ncbi.nlm.nih.gov/10434239
https://pubmed.ncbi.nlm.nih.gov/10434239